Publications

Thank you for your interest in BHE’s publications. On this page, you will find a list of our peer-reviewed journal articles, categorized by therapeutic area. To request reprints please visit our contact us page.

Alzheimer’s Disease

• Martin BC, Ricci JF, Kotzan JA, Lang K, Menzin J. The net cost of Alzheimer disease and related dementia: A population-based study of Georgia Medicaid recipients. Alzheimer Dis Assoc Disord. 2000;14(3):151-159.
• Menzin J, Lang K, Friedman M, Neumann P, Cummings J. The economic cost of Alzheimer’s disease and related dementias to the California Medicaid (”Medi-Cal”) Program in 1995. Am J Geriatr Psychiatry. 1999;7(4):300-308.

Cardiovascular Disease

• Lang K, Korn JR, Simko RJ, Zachry WM, Patel NV, Nair R, Menzin J. Development of an interactive model of the burden of future coronary heart disease from an employer perspective. J Occup Environ Med. 2010 Sep;52(9):851-7.
• Menzin J, Boulanger L, Tang S, Thakker K, Nissen S. Cost analysis of amlodipine versus enalapril in patients with coronary heart disease and normal blood pressure: findings from the CAMELOT economic substudy. Appl Health Econ Health Policy 2008;6(2-3):157-62.
• Zhang B, Menzin J, Friedman M, Korn JR, Burge RT. Predicted coronary risk for adults with coronary heart disease and low HDL-C: an analysis from the National Health and Nutrition Examination Survey. Cur Med Res Opin. 2008; 24(9):2711-2717.
• Menzin J, Wygant G, Hauch O, Jackel J, Friedman M. One-year costs of ischemic heart disease among patients with acute coronary syndromes: findings from a multi-employer claims database. Cur Med Res Opin. 2008; 24(2):461-468.
• Boulanger L, Kim J, Friedman M, Hauch O, Foster T, Menzin J.Patterns of use of antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practice. Int J Clin Pract. 2006; 60(3):258-264.
• Menzin J, Boulanger L, Hauch O, Friedman M, Marple CB, Wygant G, Hurley JS, Pezzella S, Kaatz S. Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: A multi-site managed-care study. Ann Pharmacother. 2005;39(3):446-51.
• Menzin J, Foster T, Audette R. Socioeconomic implications of long-term warfarin use. Dis Manag Health Outcomes. 2004;12(6):385-92.
• Menzin J, Lang K, Elliott WJ, Boulanger L, Arocho R, Tran MH, Friedman, M. Adherence to calcium channel blocker therapy in older adults: a comparison of amlodipine and felodipine. J Int Med Res. 2004 May-Jun;32(3):233-9.
• Pegus C, Bazzarre TL, Brown JS, Menzin J. Effect of the Heart at Work program on awareness of risk factors, self-efficacy, and health behaviors. J Occup Environ Med. 2002; 44(3):228-36.

Chronic Respiratory Disease

• Menzin J, Boulanger L, Marton J, Guadano L, Dastani H, Dirani R, Phillips A, Shah H. The economic burden of chronic obstructive pulmonary disease (COPD) in a US Medicare population. Respir Med. 2008;102:1248-1256.
• Foster TS, Miller JD, Marton JP, Caloyeras JP, Russell MW, Menzin J. Assessment of the economic burden of COPD in the US: A review and synthesis of the literature. COPD. 2006; 3(4): 211-218.
• Marton J, Boulanger L, Friedman M, Dixon D, Wilson J, Menzin J. Assessing the costs of chronic obstructive pulmonary disease: The state Medicaid perspective. Respir Med. 2006; 100(6):996-1005.
• Miller JD, Foster T, Boulanger L, Chace M, Russell MW, Marton JP, Menzin J. Direct costs of COPD in the US: An analysis of Medical Expenditure Panel Survey (MEPS) data. COPD. 2005;2(3):311-318.

Diabetes

• Menzin J, Korn JR, Cohen J, Lobo F, Zhang B, Friedman M, Neumann PJ. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus. JMCP 2010;16(4):264-275.
• Menzin J, Langley-Hawthorne C, Friedman M, Boulanger L, Cavanaugh R. Potential short-term economic benefits of improved glycemic control: A managed-care perspective. Diabetes Care. 2001;24(1):51-5.

Hemorrhage

• Menzin J, White LA, Friedman M, Nichols C, Hoesche J, Bergman GE, Jones C. Factors Associated with Failure to Correct the INR following Fresh Frozen Plasma Administration among Patients Treated for Warfarin-related Major Bleeding: An Analysis of Electronic Health Records. Forthcoming 2012, Thrombosis and Haemostasis.
• Menzin J, Hoesche J, Friedman M, Nichols C, Bergman GE, Crowther M, Garcia D, Jones C. Failure to Correct International Normalized Ratio and Mortality Among Patients with Warfarin-related Major Bleeding: An Analysis of Electronic Health Records. Forthcoming 2012, Journal of Thrombosis and Haemostasis.
• Boulanger L, Joshi AV, Tortella BJ, Menzin J, Caloyeras JP, Russel MW. Excess mortality, length of stay, and costs associated with serious hemorrhage among trauma patients: Findings from the National Trauma Data Bank. Am Surg. 2007: 73:1269-1274.
• Russell MW, Joshi AV, Neumann PJ, Boulanger L, Menzin J.Predictors of hospital length of stay and cost in patients with intracerebral hemorrhage. Neurology. 2006; 67(7): 1279-81.
• Russell MW, Boulanger L, Joshi AV, Neumann PJ, Menzin J.The economic burden of intracerebral hemorrhage: Evidence from managed care. Manag Care Interface. 2006; 19(6):24-29.
• Boulanger L, Hauch O, Friedman M, Foster T, Dixon D, Wygant G, Menzin J. Warfarin exposure and the risk of thromboembolic and major bleeding events among Medicaid patients with atrial fibrillation. Ann Pharmacother. 2006; 40(6):1024-1029.

Infection

• Menzin J, Meyers JL, Friedman M, Korn JR, Perfect JR, Langston AA, Danna RP, Papadopoulous G. The economic costs to US hospitals of invasive fungal infections in transplant patients. Am J Infec Control. 2011 May;39(4):e15-20.
• Menzin J, Marton JP, Meyers JL, Carson RT, Rothermel CD, Friedman M. Inpatient treatment patterns, outcomes, and costs of skin and skin structure infections because of Staphylococcus aureus. Am J Infec Control. 2010;38(1):44-49.
• Menzin J, Meyers J, Friedman M, Perfect J, Langson A, Danna R, Papadopoulos G. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health-Syst Pharm 2009;66:1711-7.
• Marton JP, Jackel JL, Carson RT, Rothermel CD, Friedman M, Menzin J. Costs of skin and skin structure infections due to staphylococcus aureus: an analysis of managed-care claims. Curr Med Res Opin. 2008;24(10):2821-2828.
• Menzin J, Lang KM, Friedman M, Dixon D, Marton JP, Wilson J. Excess mortality, length of stay, and costs associated with serious fungal infections among elderly cancer patients: Findings from linked SEER-Medicare data. Value Health. 2005;8(2):140-8.

Kidney Disease

• Menzin J, Lines LM, Weiner DE, Neumann PJ, Nichols C, Rodriguez L, Agodoa I, Mayne T. A review of the costs and cost effectiveness of interventions in chronic kidney disease: implications for policy. Pharmacoeconomics 2011;29:839-861

Migraine

• Brown JS, Neumann PJ, Papadopoulos G, Ruoff G, Diamond M, Menzin J. Migraine frequency and health utilities: findings from a multi-site survey. Value Health. 2008;11(2),315-321.
• Brown JS, Rupnow MFT, Neumann P, Friedman M, Menzin J.Cost effectiveness of topiramate in the prevention of migraines in the United States: an update. Manag Care Interface. 2006; 19(12): 31-38.
• Brown JS, Papadopoulos G, Neumann P, Price M, Friedman M, Menzin J. Cost-effectiveness of migraine prevention: The case of topiramate in the United Kingdom. Cephalalgia. 2006; 26(12): 1473-82.
• Brown JS, Papadopoulos G, Neumann PJ, Friedman M, Miller JD, Menzin J, Cost-effectiveness of topiramate in migraine prevention: Results from a pharmacoeconomic model of topiramate treatment. Headache. 2005;45:1012-1022.

Oncology

• White LA, Menzin J, Korn JR, Friedman M, Lang K, Ray S.Medical Care Costs and Survival Associated with Hepatocellular Carcinoma Among the Elderly. Forthcoming 2012, Clinical Gastroenterology and Hepatology.
• Lang K, Lines LM, Lee DW, Korn JR, Earle CC, Menzin J.Trends in healthcare utilization among older Americans with colorectal cancer: A retrospective database analysis. BMC Health Serv Res 2009;9:227.
• Lang K, Korn JR, Lee DW, Lines LM, Earle CC, Menzin J.Factors associated with improved survival among older colorectal cancer patients in the US: A population-based analysis. BMC Cancer 2009;9:227.
• Lang K, Lines LM, Lee DW, Korn JR, Vanness DJ, Earle C, Menzin J. Lifetime and treatment-phase costs associated with colorectal cancer: Evidence from SEER-Medicare data.Clin Gastroenterol Hepatol. 2009 Feb;7(2):198-204.
• Lang K, Sussman M, Friedman M, Su J, Kan H, Mauro D, Menzin J. Incidence and costs of treatment-related complications among patients with advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2009;135(6):582-588.
• Menzin J, Lines LM, Manning LN. The economics of squamous cell carcinoma of the head and neck. Curr Opin Otolaryngol Head Neck Surg. 2007; 15: 58-73.
• Lang K, Earle CC, Foster T, Dixon D, Van Gool R, Menzin J.Trends in the treatment of acute myeloid leukemia in the elderly. Drugs Aging. 2005; 22(11):943-955.
• Lang K, Menzin J, Earle C, Jacobson J, Hsu MA. The economic cost of squamous cell cancer of the head and neck: Findings from linked SEER-Medicare data. Arch Otolaryngol Head Neck Surg. 2004;130:1269-75.
• Menzin J, Lang K, Earle C, Glendenning GA. Treatment patterns, outcomes and costs among elderly patients with chronic myeloid leukemia: A population based analysis. Drugs Aging. 2004; 21(11):737-46.
• Menzin J, Lang K, Earle CC, Kerney D, Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med. 2002; 162(14):1597-603.
• Lang K, Menzin J, Earle CC, Mallick R. Outcomes in patients treated with gemtuzumab ozogamicin for relapsed acute myelogenous leukemia. Am J Health Syst Pharm. 2002; 59(10):941-8.

Psychiatry

• Sussman M, Friedman M, Korn JR, Hassan M, Kim J, Menzin J. The Relationship between Use of Antidepressants and Resource Utilization among Patients with Manic or Mixed Bipolar Disorder Episodes: Findings from a Managed Care Setting. Forthcoming 2012, Journal of Affective Disorders.
• Lang K, Korn J, Muser E, Choi JC, Abouzaid S, Menzin J.Predictors of medication nonadherence and hospitalization in Medicaid patients with Bipolar I Disorder given long-acting or oral antipsychotics. J Med Econ. 2011;14(2):217-26.
• Lang K, Meyers JL, Korn JR, Lee S, Sikirica M, Crivera C, Dirani R, Menzin J. Medication adherence and hospitalization among patients treated with long-acting therapies or oral antipsychotics in a large state Medicaid program. Psychiatr Serv 2010 61: 1239-1247
• Menzin J, Sussman M, Tafesse E, Duczakowski C, Neumann P, Friedman M. A model of the economic impact of a bipolar disorder screening program in primary care. J Clin Psych 2009 Sep;70(9):1230-6.
• Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR.Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv. 2003; 54:719–23.

Sleep Disorders

• Menzin J, Lang K, Levy P, Levy E. A general model of the effects of sleep medications on the risk and cost of motor vehicle accidents and its application to France. Pharmacoeconomics. 2001;19(1):69-78.

Smoking

• Menzin J, Lines LM, Marton J. Estimating the short-term clinical and economic benefits of smoking cessation: do we have it right? Expert Rev Pharmacoeconomics Outcomes Res 2009;9(3):257-264.

Surgery

• Menzin J, Zhang B, Neumann PJ, Lines LM, Polly DW, Barnett-Meyers S, Fontes R, Traynelis VC. A health-economic assessment of cervical disc arthroplasty compared with allograft fusion. Techniques in Orthopedics. 2010;25(2):133-137.
• Zhang B, Hepner DL, Tran MH, Friedman M, Korn JR, Menzin J. Neuromuscular blockade, reversal agent use, and operating room time: retrospective analysis of US inpatient surgeries. Current Medical Research and Opinion. 2009;25(4):943-950.